IGM Biosciences (IGMS) Merged; $1.247/Share Cash and CVR; S-8 Withdrawals

IGM Biosciences completed a merger into Concentra Biosciences and terminated its pending employee equity registrations.

Accepted by SEC EDGAR 08/14/2025 - 04:12 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

IGM Biosciences completed a merger into Concentra Biosciences and terminated its pending employee equity registrations. Under a Merger Agreement dated July 1, 2025, the company was merged into a Concentra subsidiary on August 14, 2025, and became a wholly owned subsidiary of Concentra. Each outstanding public share (with limited exceptions) was converted into $1.247 in cash per share plus one non-transferable contingent value right per share. As a result, the registrant has ended all offerings under multiple Form S-8 registration statements and filed post-effective amendments to withdraw any unissued and unsold securities that remained registered.

Positive

• Merger closed with explicit transaction terms: $1.247 cash per share plus one contingent value right per share
• Registrant completed required post-effective amendments to withdraw and remove unsold registered securities, meeting its filing undertakings
• Clear administrative resolution of multiple Form S-8 registration statements, simplifying the company’s outstanding registered equity

Negative

• Registered shares for employee plans were removed, meaning those securities are no longer available under the referenced Form S-8 offerings
• Employee equity previously covered by the registrations will be affected by the Merger conversion (cash and non-transferable CVRs), limiting transferability as described

Insights

M&A Specialist

TL;DR: IGM was acquired; shareholders received $1.247 cash plus a contingent value right; employee equity registrations were withdrawn.

The filing documents a closing of a merger that materially alters corporate status: IGM is now a wholly owned subsidiary of Concentra and equity previously registered for employee plans has been removed from registration. The cash consideration of $1.247 per share and issuance of non-transferable contingent value rights are explicit transaction terms. The post-effective amendments properly terminate the Form S-8 offerings, removing remaining unissued securities from the market. This is a definitive corporate control change with clear administrative follow-through in securities registration.

Corporate Governance Expert

TL;DR: Transaction closed and the company completed required post-effective S-8 withdrawals; employee equity instruments are no longer available under those registrations.

The registrant fulfilled its undertakings to withdraw unsold registered shares after the Merger. The filing lists multiple Form S-8 registration numbers and specifies the classes and counts of shares originally covered, now removed. The conversion mechanics—cash plus a contractual contingent value right—are stated, and the filing confirms termination of the effectiveness of the referenced registration statements. The document is procedural but follows required governance and securities rules for post-closing registration cleanup.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IGM Biosciences (IGMS) shareholders receive in the merger?

Each share (excluding treasury shares, shares owned by Parent/Merger Sub, and properly appraising holders) was converted into $1.247 in cash plus one non-transferable contractual contingent value right per share.

Why did IGM file post-effective amendments to its Form S-8 registrations?

The registrant undertook to remove from registration any securities remaining unsold at the termination of the offerings; following the Merger and termination of offerings, it withdrew and removed those unissued and unsold securities.

Which Form S-8 registration statements were terminated?

The filing refers to multiple post-effective amendments to Form S-8 registration numbers including 333-233826, 333-237411, 333-248111, 333-254877, 333-263927, 333-270991, 333-277744, and 333-285602, and states the effectiveness of those registration statements was terminated for remaining unsold securities.

When did the Merger become effective?

The Merger closed and became effective on August 14, 2025, per the filing.

Did the filing state the number of shares covered by the original S-8 registrations?

Yes; the filing lists specific share counts covered under each registration statement for the 2018 Plan, ESPP, and the 2010 Stock Plan as originally registered, and indicates those unsold shares were removed from registration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

As filed with the Securities and Exchange Commission on August 14, 2025

Registration No. 333-233826

Registration No. 333-237411

Registration No. 333-248111

Registration No. 333-254877

Registration No. 333-263927

Registration No. 333-270991

Registration No. 333-277744

Registration No. 333-285602

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-233826

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-237411

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-248111

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-254877

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-263927

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-270991

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-277744

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-285602

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

IGM BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware		77-0349194
(State or other jurisdiction of incorporation or organization)		(IRS employer identification number)

4747 Executive Drive, Suite 210

San Diego, California 92121

(Address of Principal Executive Offices, including Zip Code)

Amended and Restated 2018 Omnibus Incentive Plan

Amended and Restated 2019 Employee Stock Purchase Plan

Amended and Restated 2010 Stock Plan

(Full title of the Plans)

Michael Hearne

Chief Financial Officer

IGM Biosciences, Inc.

4747 Executive Drive, Suite 210

San Diego, California 92121

(858) 281-5372

(Name, Address and Telephone Number, including Area Code, of Agent for Service)

Copies to:

Ryan A. Murr

Gibson, Dunn & Crutcher LLP

One Embarcadero Center Suite 2600

San Francisco, California 94111

(415) 393-8200

Tony Jeffries

Robert T. Ishii

Jennifer Knapp

Ethan Lutske

Wilson Sonsini Goodrich & Rosati, P.C.

650 Page Mill Road

Palo Alto, California 94304

(650) 493-9300

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer, “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer		☐		Accelerated filer		☐
Non-accelerated filer		☒		Smaller reporting company		☒
				Emerging growth company		☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

EXPLANATORY NOTE

DEREGISTRATION OF UNSOLD SECURITIES

These Post-Effective Amendments (the “Post-Effective Amendments”) filed by IGM Biosciences, Inc., a Delaware corporation (the “Registrant”), to deregister all shares of the Registrant’s common stock, $0.01 par value per share (the “Shares”), remaining unissued under the following Registration Statements on Form S-8 (each, a “Registration Statement”, and collectively, the “Registration Statements”) filed by the Registrant with the U.S. Securities and Exchange Commission (the “Commission”).

• Registration Statement on Form S-8 (No. 333-233826) pertaining to the registration of (i) 4,372,807 Shares issuable under the Amended and Restated 2018 Omnibus Incentive Plan (the “2018 Plan”), (ii) 280,000 Shares issuable under the Amended and Restated 2019 Employee Stock Purchase Plan (the “ESPP”) and (iii) 595,832 Shares issuable under the Amended and Restated 2010 Stock Plan.

• Registration Statement on Form S-8 (No. 333-237411) pertaining to the registration of (i) 964,487 Shares issuable under the 2018 Plan and (ii) 241,121 Shares issuable under the ESPP.

• Registration Statement on Form S-8 (No. 333-248111) pertaining to the registration of (i) 257,248 Shares issuable under the 2018 Plan and (ii) 64,312 Shares issuable under the ESPP.

• Registration Statement on Form S-8 (No. 333-254877) pertaining to the registration of (i) 1,278,965 Shares issuable under the 2018 Plan and (ii) 319,741 Shares issuable under the ESPP.

• Registration Statement on Form S-8 (No. 333-263927) pertaining to the registration of (i) 1,299,920 Shares issuable under the 2018 Plan and (ii) 324,980 Shares issuable under the ESPP.

• Registration Statement on Form S-8 (No. 333-270991) pertaining to the registration of (i) 1,723,292 Shares issuable under the 2018 Plan and (ii) 430,823 Shares issuable under the ESPP.

• Registration Statement on Form S-8 (No. 333-277744) pertaining to the registration of (i) 4,507,245 Shares issuable under the 2018 Plan and (ii) 560,000 Shares issuable under the ESPP.

• Registration Statement on Form S-8 (No. 333-285602) pertaining to the registration of (i) 2,385,497 Shares issuable under the 2018 Plan and (ii) 560,000 Shares issuable under the ESPP.

The Registrant is filing these Post-Effective Amendments to withdraw and remove any unissued and unsold securities issuable by Registration pursuant to the above-referenced Registration Statements.

On July 1, 2025, the Registrant entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Concentra Biosciences, LLC, a Delaware limited liability company (“Parent”), and Concentra Merger Sub V, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”). Pursuant to the Merger Agreement, on August 14, 2025, Merger Sub was merged with and into the Registrant with the Registrant surviving as a wholly owned subsidiary of Parent (the “Merger”). In the Merger, each share of Common Stock (the “Shares”) (other than (i) Shares owned or held in the Company’s treasury immediately prior to the Effective Time, (ii) Shares owned directly or indirectly by Parent or Merger Sub immediately prior to the Effective Time and (iii) Shares held by any stockholder of the Registrant who properly exercised appraisal rights under Delaware law) was converted into the right to receive (i) $1.247 per Share in cash and (ii) one non-transferable contractual contingent value right for each Share.

As a result of the Merger, the Registrant has terminated all offerings of its securities pursuant to the Registration Statements. In accordance with an undertaking made by the Registrant in each of the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities that had been registered for issuance that remain unsold at the termination of the offerings, the Registrant hereby removes from registration all such securities registered under the Registration Statements that remain unsold as of the date hereof and terminates the effectiveness of the Registration Statements.

SIGNATURE

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on August 14, 2025. No other person is required to sign these Post-Effective Amendment to the Registration Statements in reliance on Rule 478 of the Securities Act of 1933, as amended.

IGM BIOSCIENCES, INC.

By: /s/ Michael Hearne

Name: Michael Hearne

Title: Chief Financial Officer